Share this article
Share this article
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development.
Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. The partners had recently completed
in vitro antiviral cell-based studies and
Share this article
Share this article
SAN JOSE, Calif., April 5, 2021 /PRNewswire/ Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.
Anixa and OntoChem are seeking to develop an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. The partners have recently completed POC studies in a Syrian Hamster model of the Covid-19 disease. Two potential compounds were evaluated as well as Remdesivir. Data showed that administration of the drugs to infected hamsters did not cause any noticeable adverse effects, and monitoring of weight and general animal behavior demonstrated comparable efficacy of both Anixa compounds as well as Remdesivir. Viral shedding da
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Corticosteroid receptor inhibitor shows anti-SARS-CoV-2 activity in vivo
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To date, SARS-CoV-2 has infected over 112 million people and has been responsible for over 2.48 million deaths.
While vaccines against SARS-CoV-2 are being administered globally, treatment options for those infected are still limited. A team of researchers examined PT150, which is an allosteric modulator of androgen and glucocorticoid receptors, to assess whether it had any antiviral activity or immunomodulatory activity to decrease the hyperinflammatory response of SARS-CoV-2 infection.
The researchers demonstrated PT150 as an effective inhibitor of SARS-CoV-2 infection in the Syrian golden hamster model. They found that oral PT150 given once daily for seven days prevented replication of SARS-CoV-2 in the lungs, decreased infiltration of macrophages, improved lung pathology
Share this article
ALBUQUERQUE, N.M., Dec. 15, 2020 /PRNewswire/
The Foundation for the National Institutes of Health (NIH) has recently published on their website (Home | FNIH) a summary workshop on experience with animal models of COVID-19 (SARS-CoV-2). The work was performed as part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, which is a public-private partnership aimed at prioritizing and speeding development of the most promising COVID-19 vaccines and treatments. The workshop evaluated and presented on best practices in virology, assays, and various species of animal models that are being used in the fight against COVID-19.
Lovelace Biomedical Scientist Dr. Adam Werts presented on the use of the Syrian Hamster to evaluate treatments and vaccines against the virus. The use of animal models to help advance therapeutics against this life threatening disease has been apparent during this pandemic. The science has moved faste